Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment

Reuters03-22

Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment

Clover said its subsidiary Clover HK entered into a settlement agreement with Gavi to resolve an arbitration seeking repayment of USD 224.0 million in advance purchase amounts.
The settlement includes a one-off upfront cash payment of USD 7.0 million to Gavi.
It also provides for semi-annual deferred cash payments of USD 1.5 million or a low single-digit percentage of the group’s cash balance, whichever is higher.
Additional contingent success-based payments are tied to mid-to-high single-digit percentages of the group’s future cash receipts.
Clover said the maximum cumulative amount of future payments is capped in the mid double-digit millions of dollars over a 12-year term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260322-12061993), on March 22, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621712193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-22 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621712193","market":"fut","top_or_hot":-1,"title":"Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clover said its subsidiary Clover HK entered into a settlement agreement with Gavi to resolve an arbitration seeking repayment of USD 224.0 million in advance purchase amounts.\n        </li>\n<li>\n          The settlement includes a one-off upfront cash payment of USD 7.0 million to Gavi.\n        </li>\n<li>\n          It also provides for semi-annual deferred cash payments of USD 1.5 million or a low single-digit percentage of the group’s cash balance, whichever is higher.\n        </li>\n<li>\n          Additional contingent success-based payments are tied to mid-to-high single-digit percentages of the group’s future cash receipts.\n        </li>\n<li>\n          Clover said the maximum cumulative amount of future payments is capped in the mid double-digit millions of dollars over a 12-year term.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260322-12061993), on March 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-22 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clover said its subsidiary Clover HK entered into a settlement agreement with Gavi to resolve an arbitration seeking repayment of USD 224.0 million in advance purchase amounts.\n        </li>\n<li>\n          The settlement includes a one-off upfront cash payment of USD 7.0 million to Gavi.\n        </li>\n<li>\n          It also provides for semi-annual deferred cash payments of USD 1.5 million or a low single-digit percentage of the group’s cash balance, whichever is higher.\n        </li>\n<li>\n          Additional contingent success-based payments are tied to mid-to-high single-digit percentages of the group’s future cash receipts.\n        </li>\n<li>\n          Clover said the maximum cumulative amount of future payments is capped in the mid double-digit millions of dollars over a 12-year term.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260322-12061993), on March 22, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL5XjjX3:1","article_id":"2621712193","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621712193","pubTimestamp":1774180739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clover said its subsidiary Clover HK entered into a settlement agreement with Gavi to resolve an arbitration seeking repayment of USD 224.0 million in advance purchase amounts.The settlement includes a one-off upfront cash payment of USD 7.0 million to Gavi.It also provides for semi-annual deferred cash payments of USD 1.5 million or a low single-digit percentage of the group’s cash balance, whichever is higher.Additional contingent success-based payments are tied to mid-to-high single-digit percentages of the group’s future cash receipts.Clover said the maximum cumulative amount of future payments is capped in the mid double-digit millions of dollars over a 12-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B","BK1161":"生物科技"},"translate_title":"三叶草生物制药以700万美元预付款解决全球疫苗和免疫联盟仲裁","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":0.9},"content_text":"Clover Biopharmaceuticals settles Gavi arbitration with USD 7 million upfront payment\n    \n\n\n          Clover said its subsidiary Clover HK entered into a settlement agreement with Gavi to resolve an arbitration seeking repayment of USD 224.0 million in advance purchase amounts.\n        \n\n          The settlement includes a one-off upfront cash payment of USD 7.0 million to Gavi.\n        \n\n          It also provides for semi-annual deferred cash payments of USD 1.5 million or a low single-digit percentage of the group’s cash balance, whichever is higher.\n        \n\n          Additional contingent success-based payments are tied to mid-to-high single-digit percentages of the group’s future cash receipts.\n        \n\n          Clover said the maximum cumulative amount of future payments is capped in the mid double-digit millions of dollars over a 12-year term.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260322-12061993), on March 22, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621712193","isCrawlerRequest":true}